These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 34051727)
1. Zanubrutinib-induced liver injury: a case report and literature review. Atallah E; Wijayasiri P; Cianci N; Abdullah K; Mukherjee A; Aithal GP BMC Gastroenterol; 2021 May; 21(1):244. PubMed ID: 34051727 [TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies. Ou YC; Liu L; Tariq B; Wang K; Jindal A; Tang Z; Gao Y; Sahasranaman S Clin Transl Sci; 2021 Mar; 14(2):764-772. PubMed ID: 33306268 [TBL] [Abstract][Full Text] [Related]
3. Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature. Abeles RD; Foxton M; Khan S; Goldin R; Smith B; Thursz MR; Verma S BMJ Open Gastroenterol; 2020 Nov; 7(1):. PubMed ID: 33214235 [TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328 [TBL] [Abstract][Full Text] [Related]
5. Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma. Weaver AN; Jimeno A Drugs Today (Barc); 2020 Aug; 56(8):531-539. PubMed ID: 33025948 [TBL] [Abstract][Full Text] [Related]
6. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. Geethakumari PR; Awan F Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675 [TBL] [Abstract][Full Text] [Related]
7. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873 [TBL] [Abstract][Full Text] [Related]
8. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Tam CS; Opat S; Simpson D; Cull G; Munoz J; Phillips TJ; Kim WS; Rule S; Atwal SK; Wei R; Novotny W; Huang J; Wang M; Trotman J Blood Adv; 2021 Jun; 5(12):2577-2585. PubMed ID: 34152395 [TBL] [Abstract][Full Text] [Related]
9. Nonclinical Safety Assessment of Zanubrutinib: A Novel Irreversible BTK Inhibitor. Zhang C; Tian B Int J Toxicol; 2020; 39(3):232-240. PubMed ID: 32484067 [TBL] [Abstract][Full Text] [Related]
10. Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature. Studentova H; Volakova J; Spisarova M; Zemankova A; Aiglova K; Szotkowski T; Melichar B BMC Gastroenterol; 2022 Feb; 22(1):49. PubMed ID: 35123392 [TBL] [Abstract][Full Text] [Related]
11. A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies. Song Y; Sun M; Qi J; Xu W; Zhou J; Li D; Li J; Qiu L; Du C; Guo H; Huang J; Tang Z; Ou Y; Wu B; Yu Y; Zhu J Br J Haematol; 2022 Jul; 198(1):62-72. PubMed ID: 35383885 [TBL] [Abstract][Full Text] [Related]
13. The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma. Hanna KS; Campbell M; Husak A; Sturm S J Oncol Pharm Pract; 2020 Jul; 26(5):1190-1199. PubMed ID: 32279595 [TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Tam CS; Trotman J; Opat S; Burger JA; Cull G; Gottlieb D; Harrup R; Johnston PB; Marlton P; Munoz J; Seymour JF; Simpson D; Tedeschi A; Elstrom R; Yu Y; Tang Z; Han L; Huang J; Novotny W; Wang L; Roberts AW Blood; 2019 Sep; 134(11):851-859. PubMed ID: 31340982 [TBL] [Abstract][Full Text] [Related]
15. Drug-induced severe liver injury due to Zhu L; Geng J; Xiao A J Biomed Res; 2022 May; 36(3):215-220. PubMed ID: 35965441 [No Abstract] [Full Text] [Related]
16. Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran. Lewis JH; Larrey D; Olsson R; Lee WM; Frison L; Keisu M Int J Clin Pharmacol Ther; 2008 Jul; 46(7):327-39. PubMed ID: 18793587 [TBL] [Abstract][Full Text] [Related]
17. A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment. Ou YC; Preston RA; Marbury TC; Tang Z; Novotny W; Tawashi M; Li TK; Sahasranaman S Leuk Lymphoma; 2020 Jun; 61(6):1355-1363. PubMed ID: 32031037 [TBL] [Abstract][Full Text] [Related]